Quick Answer
Design Therapeutics, Inc. reported Operating Income of -$79.47 million for fiscal year 2025.
Design Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$79.47M | -27.4% |
| 2024 | -$62.38M | +20.2% |
| 2023 | -$78.19M | -15.7% |
| 2022 | -$67.59M | -88.6% |
| 2021 | -$35.83M | -330.1% |
| 2020 | -$8.33M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.31M | -18.9% | +10.5% |
| June 30, 2025 | -$21.57M | -43.4% | -5.6% |
| March 31, 2025 | -$20.42M | -41.8% | -25.7% |
| September 30, 2024 | -$16.25M | +13.7% | -8.0% |
| June 30, 2024 | -$15.04M | +33.4% | -4.5% |
| March 31, 2024 | -$14.40M | +33.5% | +23.5% |
| September 30, 2023 | -$18.82M | +1.9% | +16.7% |
| June 30, 2023 | -$22.60M | -44.5% | -4.4% |
- Design Therapeutics, Inc. showed a decrease of -27.4% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Design Therapeutics, Inc.’s operating income has declined by 854.0% (from -$8.33 million to -$79.47 million).
- The most recent figure is from Design Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: